Q4 2024 Syndax Pharmaceuticals Inc Earnings Call Transcript

Mar 3, 2025 / 01:00 PM GMT

Release Date Price: €14.7 (+2.08%)

Transcript 10-K8-K

Key Points

Positve

Syndax Pharmaceuticals Inc (SNDX) reported its first quarter with product revenue, generating $7.7 million from Revv Forge in just five weeks post-launch.
The FDA approved Revv Forge, a first-in-class mein inhibitor, for relapse refractory acute leukemia patients with KMT2A translocation, highlighting the company's strong execution and rapid market entry.
Syndax Pharmaceuticals Inc (SNDX) has a robust financial position with $692.4 million in cash equivalents and investments, expected to fund operations through profitability.
The company is aggressively advancing its clinical development strategy for Revv Forge, with plans to file a supplemental new drug application to expand its indicated population.
Syndax Pharmaceuticals Inc (SNDX) has launched Nick Timbo in partnership with Insight, targeting chronic graft versus host disease, and is exploring further expansion opportunities.

Negative

Operating expenses for the fourth quarter were high at $104.0 million, with significant research and development and selling, general, and administrative expenses.
The company is not providing revenue guidance for 2025, which may create uncertainty for investors.
There is a reliance on a limited distribution model, which could impact inventory levels and distribution efficiency.
The competitive landscape in oncology is evolving, and Syndax Pharmaceuticals Inc (SNDX) faces challenges in maintaining its first-mover advantage.
The company has not yet announced specific plans for regulatory submissions or partnerships for Revv Forge outside the US, which could delay international market expansion.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

SNDX.OQ - Syndax Pharmaceuticals Inc
Q4 2024 Syndax Pharmaceuticals Inc Earnings Call
Mar 03, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day everyone and welcome to the Sendax 4th quarter and full year 2024 earnings conference call. Today's call is being recorded. If you'd like to ask a question following the company's prepared remarks, please press 5 during the call.

At this time, I'd like to turn the call over to Sharon Clary, head of investor relations at Senda Pharmaceuticals.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Welcome and thank you all for joining us today for a review of Synnais's 4th quarter and full year in 2024 financial and operating results. I'm

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.